Scholars Central

Conference abstract

Colorectal carcinoma in Iran: a universal strategy for immunohistochemical screening of Lynch syndrome

Authors: Ladan Goshayeshi, Alireza Khooiee, Kamran Ghaffarzadegan, Mahla Rahmani Khorram, Faraz Bishesari, Binyamin Hoseini, Abbas Esmaeielzadeh, Hooman Mosannen Mozaffari, Omid Ghanayee, S Lari, Ali Bahari, Abolghasem Allahyari, Alireza Bari, Azita Ganji, Lena Goshayeshi, Farnood Rajabzadeh, Kambiz Akha

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: A genetically inherited autosomal disorder that increases the risk of many types of cancer, especially colorectal cancer (CRC), is Lynch Syndrome (LS). Identification of these subjects improves morbidity and mortality. We aimed to assess the prevalence of LS and familial colorectal cancer type x (FCCTX) syndrome with both clinical criteria and universal strategy in Mashhad, Iran. Methods: It is a retrospective study in which we screened 322 patients with CRC between 2013 and 2016 in Mashhad, Iran. CRCs were screened based on Amsterdam II criteria, revised Bethesda guideline, and universal strategy. Information regarding the clinical criteria was obtained by interviewing the patients or, their families. Tumors were screened by pathologists with IHC staining of four Mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, and PMS2). And tumors with absent IHC staining of MLH1 were tested for BRAF mutations to exclude sporadic CRCs. Results: Of 322 CRCs, 33 cases were detected to be deficient-MMR, 22 of these had concurrent loss of MLH1 and PMS2, followed by concurrent loss of MSH2 and MSH6 in 8 CRCs. 22 cases with a loss of MLH1 underwent testing for the BRAF mutation, 4 of which were recognized as a positive BRAF mutation. Finally, 29 CRCs were detected as being positive screen for LS. A poor sensitivity (21.74%) reported for the Amsterdam II criteria and a poor positive predictive value (15.39%) for the revised Bethesda. And 4 cases detected to be FCCTX. Conclusion: LS and FCCTX were common in Iran, application of clinical criteria may not be effective enough to identify LS and at least 2-antibody panel (PMS2, MSH6) should be conducted for newly diagnosed CRCs. Further studies are necessary in FCCTX and early-onset CRCs in Iran. PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacogenomics & Pharmacoproteomics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ladan Goshayeshi”
  • BylineArticles whose byline prints “Alireza Khooiee”
  • BylineArticles whose byline prints “Kamran Ghaffarzadegan”
  • BylineArticles whose byline prints “Mahla Rahmani Khorram”
  • BylineArticles whose byline prints “Faraz Bishesari”
  • BylineArticles whose byline prints “Binyamin Hoseini”
  • BylineArticles whose byline prints “Abbas Esmaeielzadeh”
  • BylineArticles whose byline prints “Hooman Mosannen Mozaffari”